Earnings Feed
Start Free
Gossamer Bio, Inc.·4

Mar 20, 4:16 PM ET

Giraudo Bryan 4

4 · Gossamer Bio, Inc. · Filed Mar 20, 2026

Research Summary

AI-generated summary of this filing

Updated

Gossamer Bio CFO Bryan Giraudo Reprices/Exchanges Stock Options

What Happened
Bryan Giraudo, the Chief Operating Officer and Chief Financial Officer of Gossamer Bio (GOSS), exchanged (disposed to the issuer) a series of existing derivative awards and, simultaneously, received matching repriced option awards on March 19, 2026. The filing shows 11 dispositions and 11 grants, each pair for the same share counts, totaling 2,960,751 underlying shares. The issuer reduced the per-share exercise price of the repriced options to $0.45. No cash purchase or open-market sale is reported — these are option cancellations and re-grants (derivative transactions), not stock sales.

Key Details

  • Transaction date: March 19, 2026; Form 4 filed March 20, 2026.
  • Total shares involved: 2,960,751 underlying shares (sum of listed dispositions and matching grants).
  • New exercise price: $0.45 per share for the repriced options (per footnote).
  • Consideration/price shown on the Form 4: N/A for the dispositions/grants (derivative transactions).
  • Plan: Awards were under the Issuer’s 2019 Incentive Award Plan.
  • Vesting/terms: Footnote states all other terms (including vesting and term) remain unchanged except for the reduced exercise price; grants vest per the original schedule and are subject to continued service.
  • Shares owned after transaction: Not disclosed in the provided summary of this filing.
  • Timeliness: Reported the next day (Form 4 filed 3/20 for 3/19 transactions); no late filing indicated.

Context
This was a company-approved one-time option repricing (not an open-market buy or sale). For retail investors, note this transaction reflects a modification of option economics (lower exercise price) rather than an insider buying or selling stock in the market. It does not by itself indicate insider sentiment about the company’s shares; vesting remains subject to continued service.

Insider Transaction Report

Form 4
Period: 2026-03-19
Gossamer Bio, Inc.GOSS
Giraudo Bryan
COO/CFO
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−693,750→ 0 total
    Exercise: $2.88Exp: 2036-01-01→ Common Stock (693,750 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−638,000→ 0 total
    Exercise: $1.13Exp: 2035-03-03→ Common Stock (638,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−543,750→ 0 total
    Exercise: $0.97Exp: 2034-01-01→ Common Stock (543,750 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−181,250→ 0 total
    Exercise: $0.84Exp: 2033-11-19→ Common Stock (181,250 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−211,500→ 0 total
    Exercise: $1.21Exp: 2033-03-19→ Common Stock (211,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−211,500→ 0 total
    Exercise: $2.16Exp: 2032-12-06→ Common Stock (211,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−176,667→ 0 total
    Exercise: $1.36Exp: 2032-01-05→ Common Stock (176,667 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−100,000→ 0 total
    Exercise: $1.36Exp: 2031-09-16→ Common Stock (100,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−60,000→ 0 total
    Exercise: $1.36Exp: 2031-02-25→ Common Stock (60,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−47,667→ 0 total
    Exercise: $1.36Exp: 2030-02-14→ Common Stock (47,667 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−96,667→ 0 total
    Exercise: $1.36Exp: 2029-03-25→ Common Stock (96,667 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+693,750→ 693,750 total
    Exercise: $0.45Exp: 2036-01-01→ Common Stock (693,750 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+638,000→ 638,000 total
    Exercise: $0.45Exp: 2025-03-03→ Common Stock (638,000 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+543,750→ 543,750 total
    Exercise: $0.45Exp: 2034-01-01→ Common Stock (543,750 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+181,250→ 181,250 total
    Exercise: $0.45Exp: 2033-11-19→ Common Stock (181,250 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+211,500→ 211,500 total
    Exercise: $0.45Exp: 2033-03-19→ Common Stock (211,500 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+211,500→ 211,500 total
    Exercise: $0.45Exp: 2032-12-06→ Common Stock (211,500 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+176,667→ 176,667 total
    Exercise: $0.45Exp: 2032-01-05→ Common Stock (176,667 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+100,000→ 100,000 total
    Exercise: $0.45Exp: 2031-09-15→ Common Stock (100,000 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+60,000→ 60,000 total
    Exercise: $0.45Exp: 2031-02-25→ Common Stock (60,000 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+47,667→ 47,667 total
    Exercise: $0.45Exp: 2030-02-14→ Common Stock (47,667 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+96,667→ 96,667 total
    Exercise: $0.45Exp: 2029-03-25→ Common Stock (96,667 underlying)
Footnotes (2)
  • [F1]Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.
  • [F2]This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Signature
/s/ Jeff Boerneke, Attorney-in-Fact|2026-03-20

Documents

1 file
  • 4
    wk-form4_1774037809.xmlPrimary

    FORM 4